is there anything “fishy” about using omega-3 fatty acids ... · c. anxiety disorders are...
TRANSCRIPT
Is there anything “fishy” about using omega-3 fatty acids for anxiety?
A review of the current literature surrounding fish oil
supplementation for improving anxiety symptoms.
Pharmacotherapy Rounds – Friday, September 6th, 2019
Taylor Blevins, Pharm.D.
Post Graduate Year-2 Ambulatory Care/Behavioral Health Pharmacy Resident
South Texas Veterans Health Care System
The University of Texas at Austin and UT Health San Antonio
Objectives
By the end of the presentation, the audience should be able to:
1. Differentiate between symptoms of anxiety and anxiety disorders
2. Describe the potential mechanisms between omega-3 fatty acids and neuropsychiatric health
3. Formulate evidence-based recommendations for the use of omega-3 fatty acid supplements in anxiety
disorders
1 B l e v i n s
Anxiety Disorders
I. Epidemiology of anxiety disorders
a. In the United States (U.S.), anxiety disorders comprise the most common mental illness –
affecting nearly 40 million adults1-3
- Higher prevalence in females (2:1 female to male ratio)
- Specific phobias are most commonly reported source of anxiety
▪ Prevalence: specific phobias > social anxiety disorder > generalized anxiety
disorder > panic disorder
b. Approximately 31.1% of U.S. adults experience any anxiety disorder at some time in their lives
(includes obsessive compulsive disorder and post-traumatic stress disorder)1
c. Anxiety disorders are associated with a lower health-related quality of life and an increased risk of
all-cause mortality4,5
II. Anxiety symptoms and definitions
a. Anxiety is often muddled with other symptoms and conditions
b. Anxiety is a broad term used to encompass a variety of psychological, behavioral, and physical
symptoms3
c. Definitions
- Anxiety is broadly defined as an emotion characterized by worried thoughts, feelings of
tension, and physiological changes6
▪ An emotional response to the anticipation of a future threat7
- Symptoms of anxiety can manifest as thoughts, feelings, and physiological changes (eg.
sweating, increased blood pressure, jitteriness/trembling, dizziness, rapid heart rate)7,8
- Other anxiety-related terminology6-8
▪ Worry = a state of anxiety and uncertainty
▪ Fear = an emotional response to a threat, real or perceived
▪ Stress = a state of mental or emotional strain or tension resulting from adverse or
demanding circumstances
III. Formal diagnosis and characterization of anxiety disorders
a. The grouping of anxiety disorders includes generalized anxiety disorder (GAD), panic disorder (PD)
with/without agoraphobia, and social anxiety disorder7,9
- These disorders differ from one another by the types of objects/situations that induce
fear, anxiety, or avoidance behavior and the associated cognitive ideation7
b. Diagnosed per 2013 Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)7
- Different from developmentally normative or transient, often stress-induced,
fear/anxiety due to excess or persistence (i.e. typically lasting ≥6 months)
- Symptoms cause significant distress and impair social or daily functioning
- Symptoms not attributable to substance use, other medication, or another
medical/mental health condition
c. Under the previous DSM-IV, post-traumatic stress disorder (PTSD) and obsessive-compulsive
disorder (OCD) were grouped under anxiety disorders7,9
- In DSM-5 these were separated out to other categories of trauma and stressor-related
disorders and obsessive-compulsive and related disorders, respectively
2 B l e v i n s
Figure 1. Various anxiety disorders (including PTSD and OCD per DSM-IV)
d. Anxiety disorders often overlap with one another and are comorbid with other psychiatric
conditions
- Treatment may be complicated in patients who present with an overlap of more than
one anxiety disorder
- Anxiety or related symptoms can exist individually or in combination with another
psychiatric disorder
▪ Most patients with anxiety present with another psychiatric condition, commonly
depression
▪ Anxious distress has been noted as a prominent feature of both bipolar disorder
and major depressive disorder (MDD)
IV. Pathophysiology
a. Complexity of development of anxiety disorders includes genetics, neurobiological changes,
personalities, and experiences7,10
- Twin studies up to 50% heritability
- Primarily thought to be a brain stem and limbic system disorder
▪ Integration of mood modulation and cognitive functioning
▪ Fine balance between excitation and inhibition
b. There are various mechanisms that aim to describe the pathophysiology behind anxiety
disorders7,10
- Dysregulation in the hypothalamic-pituitary-adrenal (HPA) axis with excess cortisol
release
- Imbalances in gamma-amino butyric acid (GABA) and/or serotonin (5-HT), which play a
large role in modulating the activity of the limbic system and brain stem
▪ GABA is primary inhibitory neurotransmitter and 5-HT modulates GABA
- Changes in hippocampal volume and neurogenesis in the limbic system are implicated
in stress sensitivity and resiliency
V. Management/treatment
a. Psychotherapy
- Psychotherapy is considered a first-line treatment for all anxiety disorders3,7
Generalized anxiety disorder (GAD)
Panic disorder (PD) +/-agoraphobia
Social anxiety disorder (SAD)
Specific phobiasSeparation anxiety
disorder
Anxiety disorder due to another medical
conditionSelective mutism Panic attack specifier
Substance/medication-induced anxiety
disorder
Other specified anxiety disorder
Unspecified anxiety disorder
Post-traumatic stress disorder (PTSD)
Obsessive compulsive disorder (OCD)
3 B l e v i n s
- Interpersonal treatment with a focus on cognitive and behavioral techniques for
managing symptoms of anxiety
▪ Cognitive behavioral therapy (CBT)
▪ Psychotherapy is strongly recommended for PTSD – trauma-focused
psychotherapy always first-line treatment
b. Pharmacotherapy
- Antidepressants are the primary pharmacological agents used for treatment of anxiety
disorders3,7,9
▪ Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacological
agents
a. Varying Federal Drug Administration (FDA) indications for different
anxiety disorders, but SSRIs can be used off-label for other anxiety
disorders based on clinical data
b. Lack of head-to-head trials for superiority of one SSRI vs. another3
c. Meta-analysis in GAD suggests fluoxetine may have better efficacy and
sertraline with better tolerability compared to other SSRIs12
▪ Alternative antidepressant selection may include serotonin/norepinephrine
reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), or monoamine
oxidase inhibitors (MAOIs), mirtazapine3
a. SSRIs and SNRIs typically preferred over TCAs, MAOIs, and mirtazapine
due to their side effect profiles
b. See Appendix A for a list of antidepressant agents
▪ A full antidepressant response takes longer, and the response rate is lower
compared to patients with depression3,9
a. May take up to 12 weeks for maximum effect
b. During the initial 2-week period, patients are likely to experience
increased anxiety symptoms
i. This may affect treatment adherence
ii. Recommended to provide adequate counseling and establish
expectations
c. Additional improvement in GAD symptoms is not likely with an agent
and/or dose if partial response is not seen at 4 weeks13
▪ It is usually recommended to start antidepressants at half the initial dose used in
depression to minimize initial worsening of anxiety symptoms3,7,9
- Other non-antidepressant treatment options may include antihistamines, atypical
antipsychotics, GABA modulators, and much more3,7,9
▪ See appendix B for a list of specific agents
▪ NOTE: benzodiazepines may be used, but should be restricted to the lowest
effective dose and not to exceed 4 weeks in duration
a. Concerns for abuse, dependence, tolerance, and potentially dangerous or
distressing withdrawal, among others
b. Not recommended for PTSD also because of interference with
psychotherapy
- Considerations in patients who are pregnant or nursing
▪ GAD with highest prevalence during pregnancy (8.5-10.5%)14
a. An uncontrolled or poorly controlled anxiety disorder involves risks to the
mother and fetus
4 B l e v i n s
b. Associated with increased risk of postpartum depression15
▪ Treatment considerations7,61
a. Encourage psychotherapy
b. Weight risk vs. benefit of pharmacotherapy and patient preferences
c. Transplacental exposure is high for most antidepressants15,16
i. Avoid paroxetine during pregnancy
1. Crosses the placenta with increased risk of teratogenic
effects
2. Additional non-teratogenic effects the newborn may
experience could include respiratory depression, seizures,
apnea, cyanosis, etc.
ii. Sertraline and fluoxetine are the most well-studied
antidepressants in pregnancy and usually preferred
d. Antidepressant exposure through breastfeeding is generally considered to
be less than transplacental exposure, but data is limited16-18,52,53
i. SSRIs generally considered safe for breastfeeding mothers, but
lack robust evidence
ii. Most SSRIs categorized as Hale's Lactation Category L2 (probably
compatible)
c. Patient-preference plays a role in choosing psychotherapy +/- pharmacotherapy3,7,9
- Similar efficacy for acute treatment of anxiety3
- Combination treatment is ideal, but there has been no clear evidence to suggest
superiority of combination therapy vs. monotherapy for anxiety long-term outcomes3
▪ Exceptions to this include:
a. In treatment of PD and OCD, combination therapy is more efficacious11
b. Specific phobias and SAD typically treated with psychotherapy,7
c. Limited evidence supporting augmentation strategies in SAD
▪ Some guidelines specifically recommend first-line therapy as CBT +/-
antidepressant therapy – British Association for Psychopharmacology and
National Institute for Health and Care Excellence
d. Goal of treatment is remission of anxiety symptoms
- The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial provided
clinical definitions for response and remission with treatment19
▪ Response = ≥ 50% reduction in symptoms
▪ Remission = near-absence of symptoms (eg. Hamilton Anxiety Scale [HAM-A]
score <7)
- If treatment goal not achieved with first-line pharmacotherapy using an SSRI,
alternative options may include:3
▪ Switching from one SSRI to another
▪ Switching from SSRI to SNRI, or vice versa
▪ Switching to TCA
▪ Augmentation with alternative agent
- Oftentimes for anxiety, response and remission rates remain low despite psychotherapy
and/or pharmacotherapy3
- Various mental health assessments may be used to quantify and track progress
▪ See appendix C for a list of various rating scales
e. Major therapeutic phases for treatment of anxiety disorders3,7
5 B l e v i n s
Figure 2. Therapeutic phases for pharmacological treatment of anxiety disorders
- Similar therapeutic phases to treatment of depression
- Recommended to continue treatment for at least 1 year after achieving response
- Early discontinuation is associated with a high risk for relapse of symptoms
- When appropriate, discontinuation should be slow and gradual to minimize risk of
precipitating withdrawal symptoms
▪ May consider discontinuation after 12 months of treatment
▪ May taper agents up to 12 weeks – similar to treatment initiation
f. Natural and herbal remedies3
- Agents with potential benefit in anxiety may include passionflower, valerian, St. John’s
wort, kava, L-lysine, L-arginine, B vitamins, and folic acid
▪ Kava linked to hepatotoxicity – FDA warns against use
▪ St. John’s wort with many drug-drug interactions
- Recent evidence has suggested omega-3 fatty acids may provide antidepressant and
anxiolytic effects
Omega-3 Fatty Acids
I. Types of fat and fatty acids
a. There are 2 types of fat: saturated and unsaturated fats20-22
- Unsaturated fats are further subdivided into polyunsaturated and monounsaturated fats
- Under the polyunsaturated fats category, there are a few different types of
polyunsaturated fatty acids (PUFAs) – omega-6 and omega-3 fatty acids
- Omega-6 (n-6) fatty acids
▪ Implicated in pro-inflammatory processes
▪ Different types of n-6 fatty acids:
a. Linoleic acid (LA)
i. Essential fatty acid, which can only come from dietary intake
ii. From certain plants – flaxseed, soybean, walnut, canola oil
b. Arachidonic acid (AA)
i. From animal sources – poultry, eggs
ii. Abundant in brain, muscles, and liver
- Omega-3 (n-3) fatty acids
▪ Anti-inflammatory biological role
▪ Play a fundamental role in brain structure and function
▪ Different types of n-3 fatty acids:
a. Alpha-linolenic acid (ALA)
i. Essential fatty acid, which can only come from dietary intake
Acute Phase
4-6 weeks, initial response
Continuation Phase
6-12 months in remission
Maintenance Phase
>12 months in remission
6 B l e v i n s
ii. Other n-3 fatty acids are converted from ALA
iii. From certain plants – flaxseed, soybean, walnut, canola oil
b. Docosahexaenoic acid (DHA)
i. From marine sources – fish, shellfish, fish oil, krill oil
ii. High storage concentration in brain, retina, and sperm
c. Eicosapentaenoic acid (EPA)
i. From marine sources – fish, shellfish, fish oil, krill oil
ii. Dietary intake more efficient than metabolic conversion of ALA
d. Docosapentaenoic acid (DPA)
i. From marine sources (particularly salmon), grass-fed beef, and
found abundantly in human milk
ii. Most abundant n-3 fatty acid in the brain after DHA23
iii. May serve as a storage depot for EPA and DHA in the body23,24
II. Diet vs. supplementation of n-3 fatty acids
a. n-3 fatty acids are available as over-the-counter (OTC) or prescription supplementation25,54
- Commonly referred to as “fish oil” as per DHA and EPA sources in most supplements
- Concentrated EPA, DHA, or a combination of the two are commercially available in
various formulations
- Concentrated DPA not commercially available – undergoing research26
- NOTE: ~3 salmon meals/week roughly equivalent to 1 g/day of n-3 fatty acid
supplementation27
- Side effect profile of fish oil supplementation is virtually non-existent25
▪ “Fishy burps” or fishy aftertaste
▪ Gastrointestinal upset
▪ Potential to increase in bleeding risk, albeit debated in the literature
a. Bleeding time may be prolonged at doses >3g/day28
b. Overall, limited clinical evidence of prolonged bleeding
- Dosing regimens for n-3 fatty acids range between 1-4 g/day25
▪ For triglyceride-lowering effects, doses typically 2-4 g/day EPA + DHA
- Drug-drug interactions (DDIs)25
▪ No DDIs between fish oil and psychotropic medications
b. Dietary and supplement recommendations for intake of n-3 fatty acids
- The American Heart Association recommends for people without cardiovascular disease
(CVD) to eat foods rich in n-3 fatty acids at least twice/week29
- Recommended daily intake of EPA + DHA 500 mg/day per International Society for the
Study of Fatty Acids and Lipids (ISSFAL)30
- The Omega‐3 Fatty Acids Subcommittee of the Committee on Research on Psychiatric
Treatments of the American Psychiatric Association (APA) recommends eating fish ≥2
times/week for healthy adults and 1g/day of n-3 fatty acid supplementation (EPA + DHA)
for patients with mood, impulse control, or psychotic disorders31
7 B l e v i n s
Figure 3. n-3 fatty acids proposed health benefits32-37
Omega-3 Fatty Acids & Mental Health
I. Nutritional psychiatry
a. “Food and mood”
- Mental health is closely tied to nutrition
▪ Essential vitamins, minerals, and fatty acids may have a critical role in overall
brain functions, as well as, a role more specifically in neurotransmitter synthesis
and function41
▪ The brain requires essential nutrients for proper function
▪ Additionally, some foods may produce free radicals and can damage brain tissue
- A “healthy diet” consisting of high intakes of fruit, vegetables, fish, and whole grains may
decrease risk of depression39
- In countries with a higher consumption of fish, it has been observed that there is a lower
prevalence of MDD and bipolar disorder35,42,43
- In animal models, it has been found that diet manipulation can affect brain plasticity44
- Diet is likely just as important to psychiatry as it is to endocrinology, cardiology, and
gastroenterology45
b. A diet rich in vitamins in minerals can be mimicked with certain supplements
- There is growing evidence for the select use of nutrient-based supplements to address
deficiencies or augment therapy45
- Vitamin D and n-3 supplementation for mood and behaviors has been a hot topic of
research in recent years
II. Proposed mechanism of n-3 fatty acids in mood and anxiety
a. Anti-inflammatory action
- Decrease inflammation in neural tissues and directly affect cell membrane properties
related to neurotransmitter signaling46
Improved vascular function in patients with diabetes
Decreased markers of oxidative stress
Improved symptoms of heart failure
Decreased production of very-low density lipoprotein (VLDL)
Improvement in osteoarthritis-associated knee pain
Improved outcomes in critically ill patients with acute lung injury/acute respiratory distress syndrome
Improved mood
8 B l e v i n s
▪ Enhance cell membrane fluidity and neurogenesis
- Thought to be related to a decrease in prostaglandins derived from arachidonic acid (n-6),
which can lead to decreased brain-derived neurotrophic factor levels and/or alterations in
blood flow to the brain46-48
▪ Inflammation ↓ serotonin activity
▪ EPA (n-3) ↓ brain inflammation and helps ↑ neuronal release of serotonin
▪ DHA (n-3) sensitizes serotonin receptors by improving cell membrane structure
and function in post-synaptic neurons
b. Cell membrane mechanisms
- Lipid rafts are highly organized structures in the cell membrane rich in lipids, cholesterol,
and various signaling molecules (including G-protein)46-48
- Antidepressant and antipsychotic drugs have been shown to accumulate in lipid rafts
- n-3 incorporated in membrane lipid rafts and/or involved in G-protein translocation
▪ Modification of membrane signaling domains and/or modification of G-protein
within the signaling domains
a. Antidepressants activate adenylyl cyclase more efficiently resulting in
increased levels of cyclic adenosine monophosphate (cAMP)
b. Related to the above, n-3 fatty acids may have antidepressant effects via
association with lipid raft structure and release of raft-associated proteins
into non-raft sections of the membrane
III. n-supplementation and other psychiatric disorders
a. Larger body of evidence evaluating n-3 supplementation as an adjunctive therapy in MDD61-62
- Cited in the APA treatment guidelines for depression as an augmentation treatment
option
▪ Adjunctive EPA or combination of EPA + DHA n-3 supplements
▪ n-3 supplements with higher EPA percentages (i.e. ≥60%)
b. Possible association of n-3 supplementation inducing mania in patients with bipolar I disorder
- Bipolar depressive symptoms, but not manic symptoms, may be improved by adjunctive
administration of n-3 fatty acids62
Evaluation of the Literature
Table 1. Natacci L, M Marchioni D, C Goulart A, et al. Omega 3 Consumption and Anxiety Disorders: A Cross-Sectional Analysis of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Nutrients. 2018 Jun;10(6):663.
Study design Cross-sectional analysis of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort study
Objectives To evaluate whether high-consumption of n-3 fatty acids may be associated with lower prevalence of anxiety disorders
Participants
Inclusion - Adults living in Brazil
Exclusion - Use of n-3 or n-6 fatty acid supplements - Previous bariatric surgery - Consumed <500 or >4000 calories/day - Patients with missing information for main variables
9 B l e v i n s
Methods
− Cross-sectional data from the baseline examination of the ELSA-Brasil study August 2008-December 2010 (separate longitudinal study with main study outcomes evaluating type-2 diabetes and myocardial infarction)
− Food frequency questionnaire (FFQ) measuring dietary exposure over 12 months – quantified daily intake of fish and seafood (g/day), n-6 (g/day), n-3 (g/day), and the n-6:n-3 ratio
− Brazilian healthy eating index (BHEI) to evaluate dietary quality from current nutritional recommendations
− Revised Clinical Interview Schedule (CIS-R) to diagnose mental disorders following ICD-10 codes; included anxiety diagnoses of GAD, PD, SAD, phobia, or OCD
− Fasting labs to evaluate lipid panel and C-reactive protein (CRP)
− Other comprehensive questionnaires, tests, and measurements included demographics, physical activity, alcohol intake, height, weight, body mass index (BMI), blood pressure, plasma glucose, and A1c
Intervention − n/a: observational study
Outcome(s) Association between PUFA consumption and anxiety disorders
Statistical analysis
− Two-sided tests with α 0.05 for statistical significance
− Categorical variables compared with Chi-square test
− Continuous variables compare using ANOVA with post hoc Bonferroni for parametric and Kruskal-Wallis test for non-parametric variables
− Triglycerides reported as natural scales, but log-transformed for comparison
− Diet variables measured in g/day were adjusted for total energy intake and categorized into quintiles
− Log regression models to compare n-3, n-6, and the n-6:n-3 ratio
− Partially adjusted model (Model 2) for certain variables, such as physical activity, cardio risk factors, dyslipidemia, etc., and a fully adjusted model (Model 3) with all variables an additional adjustment for diet quality and MDD
− Sensitivity analyses performed and a Holm-Bonferroni test to adjust for multiple comparisons
Results
− Total participants n=12,268 (1893 with anxiety disorders [15.4%] and 10375 without [84.6%])
− Statistically significant differences in baseline characteristics included: age, sex, race, BMI, exercise, smoking, alcohol intake, and systolic blood pressure
− Similar rates of hypertension, diabetes, and dyslipidemia between groups
− Participants with anxiety were primarily women with slightly higher BMI, less vigorous physical activity, higher frequency of smoking, and lower frequency of current use but higher frequency of past use of alcohol
Table 1a. PUFA intake and anxiety
Median n-3 and n-6 intake (interquartile range [IQR])
Anxiety (n=1893) No anxiety (n=10375)
p-value
LA, g/day 15.51 (12.89-18.39) 15.44 (12.77-18.39) 0.46
AA, g/day 0.26 (0.17-0.38) 0.26 (0.17-0.41) 0.01
ALA, g/day 2.30 (1.94-2.74) 2.31 (1.95-2.72) 0.34
EPA, g/day 0.13 (0.05-0.21) 0.14 (0.06-0.27) <0.0001
DPA 0.12 (0.05-0.21) 0.13 (0.06-0.23) <0.0001
DHA, g/day 0.42 (0.14-0.79) 0.46 (0.20-0.88) <0.0001
PUFA, g/day 19.13 (16.17-22.43) 19.2 (16.17-22.61) 0.48
n-3 total 3.01 (2.42-3.84) 3.10 (2.47-4.03) <0.0001
n-6 total 15.77 (13.14-18.66) 15.72 (13.05-18.73) 0.57
n-6:n-3 ratio 5.19 (4.15-6.45) 5.1 (3.97-6.27) <0.0001
10 B l e v i n s
− Association of lower overall n-3 total intake (including EPA, DPA, DHA, but not ALA) and higher n-6:n-3 ratio in participants with anxiety
− Additional variables were tested (including depression), but all associations lost significance after multivariate adjustment
Author’s conclusions
− Inverse association between total n-3, EPA, DPA, and DHA intake and anxiety
− Cross-sectional analysis with a calculated prevalence of 15.4% of participants with anxiety similar to previously reported rates of anxiety in Brazil
− Similar results as compared to previous literature in anxiety and anxiety-related disorders
Critique
Strengths
− Diagnosis of anxiety disorder
− Large sample size
− Review of baseline characteristics in those with vs. without anxiety
− Adjustments with multivariate analysis
Limitations
− Diet measured at single point in time (at baseline)
− Diet self-reported – recall bias
− Study not performed in U.S.
− Mental health diagnoses assessed by lay interviewers
− Included OCD in anxiety disorder cohort (separate in DSM-5)
− Not looking at n-3 fatty acid supplementation outside of diet
− Multivariate analysis lost significance
Take home points
There was an inverse association between n-3 dietary intake and the presence of anxiety and an association between the n-6:n-3 ratio and anxiety. But there was not a strong association noted for n-6 intake alone and anxiety. After adjusting for depression and multivariate analyses associations lost significance, which may be related to anxiety and depression often co-occurring. It is difficult to discern whether differences in baseline characteristics confound the associations; cross-sectional analysis does not give us causality, only associations.
Table 2. Additional literature for dietary intake of n-3 fatty acids in anxiety
Primary Literature Key Information
Jacka, et al. (2013)57 − Observational cross-sectional analysis of Australian women (n=935)
− Structured Clinical Interview for DSM-IV-TR Research Version, Non-patient edition) assessed depressive and anxiety disorders
− Significant association for low total n-3 fatty acids, DPA, EPA, and DHA with anxiety disorders (p<0.0001)
− Inverse, linear association between intake of DHA and rates of anxiety disorders
− Relationship between DHA and depressive disorders may be non-linear
11 B l e v i n s
Table 3. Kiecolt-Glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain, Behavior, and Immunity. 2011 Nov 1;25(8):1725-34.
Study design Parallel group, placebo-controlled, double-blind randomized control trial (RCT) in U.S.
Objectives To determine whether n-3 decreases proinflammatory cytokine production and depressive and anxiety symptoms in healthy young adults
Participants
Inclusion - First and second-year medical students
Exclusion - High fish intake - Fish oil or flaxseed supplementation - Smoking, alcohol, or drug abuse - Chronic illness inflammatory/endocrine - Lipid-altering drugs - Beta-blockers, steroids, ACE-inhibitors - Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) - Use of psychoactive medications
Methods
− August 2007-December 2009; block randomization to intervention or placebo
− Baseline 2 visits (3 weeks apart): visit 1 lower stress time/non-exam, visit 2 day before an exam/high stress; additional 4 visits after randomization x 12 weeks
− Baseline height, weight, central adipose tissue
− FFQ reported, Pittsburgh Sleep Quality Index with Pittsburgh Sleep Diary, and 7-day Physical Activity Recall at first and last visits
− Modified version of the Health Review administered every visit assessing side effects
− Center for Epidemiological Studies Depression Scale (CES-D) and Beck Anxiety Inventory administered at each visit
− Fasting labs at each visit to assess cytokine assays (interleukin 6 [IL-6] and tumor necrosis factor alpha [TNF-α]) and fatty-acid analyses
Intervention − 2.5 g/day n-3 fatty acid supplement (OmegaBrite® 7:1 EPA/DHA) vs. matching placebo
− Adherence measured via pill pack/unused pills at follow-up visits
Outcomes Primary (1’) – inflammatory: changes in serum and stimulated IL-6 and TNF-α production Secondary (2’) – mood: changes in anxiety and depressive symptoms
Statistical analysis
− Two-sided tests with α 0.05
− Mixed models test effects of supplementation, unstructured variance-covariance estimate error, natural log transformation for residual not normally distributed
− Differences in adverse effects were evaluated using Fischer’s exact test
− James’ blinding indices used to assess effectiveness of blinding
Results
− Total participants n=68
Table 3a. Baseline characteristics
Mean age, years (Standard Deviation [SD]) 23.65 (1.87)
Female Sex, % 44%
Race, %
White 67.6% Black 3%
Asian 17.7% Other 11.7%
Sagittal abdominal diameter, cm 18
Median Beck Anxiety (Interquartile range [IQR])
Placebo 2.5 (1-4.5) Supplement 3.5 (2-6)
Median CES-D (IQR) Placebo 5.25 (3.5-7.5) Supplement 6.25 (4-8)
12 B l e v i n s
− No significant differences in baseline characteristics
− No significant differences in self-reported diet via FFQ from baseline to 12 weeks
− Reported meds other than intervention (did not differ between groups): multivitamins, birth control, antihistamines, and antibiotics
− 99% of participants completed the 12-week study
− >95% adherence in each arm; no differences between groups
− No significant differences in side effects between supplement vs. placebo
− Blinding considered adequate; evaluated using James’ blinding indices (0.55)
− Baseline EPA or DHA similar in labs at baseline between groups; 6-fold (with n-3 supplement) and 0.5-fold (placebo) increase in plasma levels by 3-weeks of intervention
− 14% reduction in the geometric mean of IL-6 cytokine stimulation, but no significant correlations with anxiety or depression scores in the supplement or placebo groups
− 20% reduction in the geometric mean of anxiety symptoms
− Significant negative correlation between plasma n-3 levels and anxiety (r= -0.39, p=0.0006) and positive association between n-6:n-3 ratio and anxiety (r=0.34, p=0.001) vs. no significant associations in placebo group
Table 3b. Outcomes for n-3 supplementation vs. placebo
Endpoint Outcome n-3 supplement
(n=34)
Placebo (n=34)
Group difference
p-value
1’ Serum cytokines log(IL-6)
log(TNF-α)
0.051 (0.069) 0.54 (0.027)
0.054 (0.070) 0.61 (0.028)
-0.0033 (0.900) -0.076 (0.039)
0.97 0.06
1’ Stimulated cytokines log(IL-6)
log(TNF-α)
10.9 (0.050) 7.3 (0.060)
11.1 (0.051) 7.4 (0.061)
-0.15 (0.072) -0.15 (0.086)
0.04 0.08
2’ Beck Anxiety, log 0.93 (0.076) 1.2 (0.075) -0.23 (0.11) 0.04
2’ CES-D, log 1.6 (0.098) 1.6 (0.097) 0.012 (0.14) 0.93
Author’s conclusions
− n-3 supplementation can reduce inflammation and anxiety in healthy, young adults
− Reduction in anxiety symptoms associated with n-3 supplementation may link to anxiolytic benefits for individuals without an anxiety disorder diagnosis
Critique
Strengths
− Double-blind RCT with matching placebo
− Assessed symptoms of anxiety and depression
− Assessed adherence of n-3 supplementation
Limitations
− Healthy, young adults
− No clinical diagnosis of anxiety or depression
− Not taking antidepressants or other psych-related drugs
− Adherence likely not reflective of real world
− Small sample size
− Not widely generalizable
Take home points
Statistically significant improvement in anxiety symptoms, but not clinically significant. The measured ratio of n-6:n-3 was lower and stimulated cytokines were lower in patients taking the n-3 supplement. This study gives us an indication that n-3 supplementation may improve anxiety symptoms in patients with a formal diagnosis of anxiety, but this study population was healthy, young adults without a diagnosis of a mental health condition.
13 B l e v i n s
Table 4. Su KP, Tseng PT, Lin PY, et al. Association of use of omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms: A systematic review and meta-analysis. JAMA Network Open. 2018 Sep 7;1(5):e1823-7.
Study design Systematic review and meta-analysis from various countries (U.S., Japan, France, Italy, Germany, Poland, Iran, Sweden, United Kingdom, Netherlands, Israel)
Objectives To evaluate the anxiolytic effects and efficacy of n-3 fatty acid treatment in participants with elevated anxiety symptoms, irrespective of diagnosis
Participants
Inclusion - Human clinical trials - Placebo or non-placebo-controlled trials - Healthy volunteers, patients with psychiatric illness, and patients with physical illnesses other than psychiatric illnesses
Exclusion - Case reports/series - Animal studies - Review articles or meta-analyses - Studies not investigating effects of n-3 on anxiety symptoms
Methods
− Separately, two psychiatrists performed a systematic literature search through March 4, 2018 using non-specific medical subject heading terms – “omega-3,” “eisocapentaenoic acid,” “EPA,” “docosahexaenoic acid,” or “DHA” [AND] “anxiety,” “anxiety disorder,” “generalized anxiety disorder,” “agoraphobia,” “panic disorder,” or “post-traumatic stress disorder”
− Performed manual search of review article reference lists in this subject area
− Duplicates removed, titles and abstract were screened for eligibility, then full-text review analyzed and 3rd author discussed inconsistencies for final consensus
Intervention − n-3 fatty acid treatment vs. without n-3 fatty acid treatment (placebo or non-placebo)
Outcomes
Primary (1’): changes in anxiety symptoms Secondary/subgroups (2’): changes in anxiety symptoms for those with or without a “specific clinical diagnosis,” mean n-3 fatty acid daily dosage, mean age, and EPA percentage
Statistical analysis
− Random-effects meta-analysis to account for heterogeneity and Q statistic + corresponding p values inter-study variation and I2 statistic evaluating intra-study variation
− Hedges g with 95% confident intervals (CI) for effect sizes and 2-sided p values <0.05
− Variance imputation for mean and SD before and after treatment
− Intention-to-treat for participant count, or per-protocol numbers if trials only reported values for participants who completed
− Quality of blinding, randomization, and risk of bias evaluated with Jadad score
− Duval and Tweedie’s trim-and-fill test for adjusting effect sizes for potential publication bias with funnel plots and Egger regression for further assessment
− Sensitivity testing for confounding effects and potential study outliers
− Meta-regression and subgroup meta-analyses conducted for additional outcomes/differences
Results
− 19 articles; n=2240 participants (1203 n-3 treatment and 1037 without n-3 treatment)
− 16 studies placebo-controlled and 3 studies did not use placebo
− Recruited studies mean Jadad score (SD) = 3.8 (1.0)
− Significant heterogeneity between trials (Cochran Q 178.820, df 18, I2 89.934%; p
<0.001)
Table 4a. Baseline characteristics
Characteristic n-3 fatty acids
(n=1203) Control
(n=1037)
Mean age, years (SD) 43.7 40.6
Sex, female (%) 55 55
14 B l e v i n s
− No significant differences in baseline characteristics of mean age or female sex
− No significant association for drop-out rate in n-3 treatment group (p=0.71) or
duration of treatment (p=0.17)
− No significant publication bias via Egger regression and no adjustment needed per
trim-and-fill test
− Overall mean n-3 fatty acid dosage = 1605.7 mg/day
Table 4b. Outcomes for n-3 supplementation vs. control
Outcome Hedges g (CI) p-value
Overall n-3 fatty acid treatment and reduction in anxiety symptoms
0.374 (0.081-0.666)
0.01
Placebo-controlled subgroup 0.372 (0.032-0.712)
0.03
Non-placebo-controlled subgroup 0.399 (0.154-0.643)
0.001
“Specific clinical conditions” subgroup 0.512 (0.119-0.906)
0.01
Without “specific clinical conditions” subgroup -0.008 (-0.266-0.250)
0.95
n-3 supplement doses <2 g/day subgroup 0.457 (-0.077-0.991)
0.09
n-3 supplement doses >2 g/day subgroup 0.213 (0.031-0.395)
0.02
EPA <60% subgroup 0.485 (0.017-0.954)
0.04
EPA ≥60% subgroup 0.092 (-0.102-0.285)
0.35
Author’s conclusions
− n-3 fatty acid supplementation may be associated with anxiety reduction – maybe placebo effect, but appears to be some improvement in anxiety symptoms
− Anxiolytic effects appear to be stronger in patients with “specific clinical conditions”
− Additional trials are warranted to evaluate use of n-3 fatty acid supplementation as monotherapy and as augmentation in anxiety
Critique
Strengths
− First meta-analysis/review evaluating n-3 supplementation in anxiety
− Broad inclusion criteria
− Various scales evaluating symptoms
− Thorough literature search and analysis
Limitations
− Broad inclusion criteria (anxiety disorders, anxiety symptoms, PTSD, OCD)
− Selection bias
− Two articles appear to drive results
− Heterogenous population
Take home points
First thorough review of current literature evaluating effects of n-3 fatty acid supplementation and anxiety symptoms. However, “specific clinical conditions” were not always a diagnosis of anxiety. This analysis provides information for selecting doses of n-3 supplementation and EPA concentration for anxiety. Further research is warranted for n-3 supplementation in specific subgroups of anxiety disorders.
15 B l e v i n s
Table 5. Case of n-3 fatty acid supplementation and increase in symptoms of anxiety
Case Report Key Information
Blanchard, et al. (2015)56 − 54-year-old man on fluoxetine and n-3 supplement for MDD with remission of depressive symptoms
− n-3 supplement (6:1 EPA to DHA) dosing: 2x 1g soft gels/day
− Tapered off fluoxetine; continued n-3 supplement
− Increase in general anxiety and insomnia/nighttime awakenings
− Symptoms resolved with discontinuation of n-3 supplement
Table 6. Additional trials for n-3 fatty acids in anxiety and anxiety-related disorders (previously in DSM-4)
Primary Literature Key Information
Fux, et al. (2004)58
− Placebo-controlled, cross-over trial with a small sample of 11 patients with OCD on stable maximally tolerated dose of SSRI treated with matching placebo vs. 2g/day n-3 supplement (96% EPA) x 6 weeks
− Baseline Hamilton Rating Scales for depression (HAM-D) and HAM-A scores of 11.3 (±7) and 14.3 (±8) respectively – no diagnosis of major depression and mild anxiety
− Statistically significant/clinically insignificant change in Yale–Brown Obsessive-Compulsive Scale (YBOCS) (mean 17.6 [±6] by week 6 on placebo and to 18.5 [±4] on EPA, p=0.001); no changes in HAM-D or HAM-A
Zeev, et al. (2005)59 − Open-label trial with a small sample of 6 patients with PTSD
− Continued psychotropics + 2g/day n-3 supplement (96% EPA) x 12 weeks
− 2 dropouts during first 4 weeks and “the only statistically significant change was a marked worsening of the avoidance subscale in all three of the four patients who demonstrated a general tendency towards worsening scores on all scales.”
Buydens-Branchey, et al. (2008)60
− Double-blind, randomized trial with a small sample size of 22 patients undergoing substance abuse outpatient treatment program treated with placebo vs. combination n-3 supplement 5 caps/day (EPA+DHA) x 12 weeks (after completing 12 weeks of initial rehab)
− Patients with diagnosis of MDD or bipolar disorder excluded
− Significant decreases in anger and anxiety scores with large effect sizes (f=0.0506 and f=0.567, respectively)
Lesperance, et al. (2011)56 − High-EPA n-3 fatty acid supplementation reduced depressive symptoms only in patients without comorbid anxiety
Conclusions and Evidence-based Recommendations
I. A diet rich in n-3 fatty acids is inversely associated with anxiety disorders49,51,58-59,61
II. May consider n-3 fatty acid supplementation as below; see Figure 449-51,56-60
a. Monitoring
- Track changes in anxiety symptoms through mental health assistants (eg. GAD-7)
- No efficacy lab monitoring recommended for clinical practice with n-3 fatty acid
supplementation
- Monitor for signs or symptoms of unusual bruising/bleeding
▪ Bleeding time may be prolonged at n-3 doses >3g/day31
▪ Possible increased risk of bleeding in combination with SSRI
III. Further research is warranted using n-3 fatty acids in a patient population with a formal diagnosis of an
anxiety disorder (eg. GAD)
Would recommend healthy, balanced diet and dietary consistency
- Increase consumption of fresh fruits, vegetables, whole grains, and n-3 fatty acids (anti-inflammatory fatty acids)
-Llimit consumption of processed foods (pro-inflammatory n-6 fatty acids)
-Consider referral to nutritionist for meal planning and additional nutritional education (eg. Mediterranean diet)
Would consider n-3 fatty acid supplementation for the following
- Consider trial of n-3 fatty acid supplementation:
- GAD, substance-induced anxiety disorder, unspecified anxiety disorder, other anxiety disorder, or anxiety due to
another medical condition (particularly CVD): consider antidepressant +/- psychotherapy +/- n-3 supplement
augmentation
- PD or OCD: consider with antidepressant + psychotherapy +/- n-3 supplement augmentation
- For patients unwilling to trial antidepressants or other anxiolytics (except PD or OCD): consider psychotherapy
+/- n-3 supplementation
- Consider for patients interested in natural supplementation
- Consider for patients who are pregnant or nursing
- Fish oil supplement preferred over many dietary marine sources of n-3 fatty acids
- Avoid mercury-containing fish during pregnancy
- High-quality fish oil – purified, without concerns for mercury
- n-3 supplement with safe side effect profile
- n-3 fatty acid supplement selection: combination EPA (<60%) + DHA
- n-3 supplementation ≥ 2 g/dayWould NOT recommend/exercise caution with n-3 fatty acid supplementation for the following
- PTSD due to possible worsening of symptoms (particularly with high EPA concentration n-3 supplements)
- SAD or specific phobias due to lack of evidence supporting augmentation; typically treated with psychotherapy alone
- Would not recommend n-3 supplements with high EPA concentration – ≥60% EPA in treatment of anxiety disorders
- Patients with comorbid bipolar I disorder
- n-3 supplementation may induce mania, similar to most antidepressants; no improvement in mania
- If using in patients with bipolar disorder, recommend n-3 supplementation in combination with a mood stabilizer
- Patients with high risk of bleeding or history of bleeding
- In combination with serotonergic drugs, bleeding risk may be increased
- Patients with poor adherence
- High pill burden for doses ≥2 g/day
- Minimize compromising primary antidepressant pharmacotherapy or move focus away from mainstays of therapy
Figure 4. Evidence-based recommendations when considering n-3 fatty acid supplementation in anxiety disorders
References
1. Any anxiety disorder. Mental health information: Statistics. National Institutes of Mental Health. Available
from: https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder.shtml. Accessed July 2, 2019.
2. Facts and statistics. Anxiety and Depression Association of America. Available from: https://adaa.org/about-
adaa/press-room/facts-statistics. Accessed July 2, 2019.
3. Bleakley S, Davies SJ. The pharmacological management of anxiety disorders. Progress in Neurology and
Psychiatry. 2014 Nov;18(6):27-32.
4. Stein MB, Roy-Byrne PP, Craske MG, et al. Functional impact and health utility of anxiety disorders in
primary care outpatients. Medical Care. 2005;43(12):1164-1170.
5. Tolmunen T, Lehto SM, Julkunen J, et al. Trait anxiety and somatic concerns associate with increased
mortality risk: a 23-year follow-up in aging men. Annals of Epidemiology. 2014;24(6):463-468.
6. Merriam-Webster.com. 2019. Available from: https://www.merriam-webster.com. Accessed July 7, 2019.
7. Anxiety Disorders. American Psychiatric Association. Diagnostic and statistical manual of mental disorders
(DSM-5®). American Psychiatric Association Publishing. 2013 May 22.
8. Anxiety. American Psychological Association. Available from: https://www.apa.org/topics/anxiety/.
Accessed July 10, 2019.
9. Melton ST, Kirkwood CK. Anxiety disorders: generalized anxiety, panic, and social anxiety disorders. In:
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic
Approach, 10e New York, NY: McGraw-Hill. Available from:
http://accesspharmacy.mhmedical.com.ezproxy.lib.utexas.edu/content.aspx?bookid=1861§ionid=1460
65193. Accessed July 9, 2019.
10. Martin EI, Ressler KJ, Binder E, et al. The neurobiology of anxiety disorders: brain imaging, genetics, and
psychoneuroendocrinology. Psychiatric Clinics. 2009 Sep 1;32(3):549-75.
11. Cuijpers P, Sijbrandij M, Koole SL, et al. Adding psychotherapy to antidepressant medication in depression
and anxiety disorders: a meta-analysis. Focus. 2014 Jul;12(3):347-58.
12. Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder:
systematic review and meta-analysis. British Medical Journal. 2011 Mar 11;342:d1199.
13. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders,
post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from
the British Association for Psychopharmacology. Journal of Psychopharmacology. 2014 May;28(5):403-39.
14. Sutter-Dallay AL, Giaconne-Marcesche V, Glatigny-Dallay E, et al. Women with anxiety disorders during
pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the
MATQUID cohort. European Psychiatry. 2004;19:459-463.
15. Milgrom J, Gemmil AW, Bilszta JL, et al. Antenatal risk factors for postnatal depression: a large prospective
study. Journal of Affective Disorders. 2008;108:147-157.
16. Hale TW, Rowe HE. Medications and Mother's Milk 2019, 16th ed. Plano, TX. Springer Publishing, LP; 2018.
17. Burt VK, Suri R, Altshuler L, et al. The use of psychotropic medications during breast-feeding. American
Journal of Psychiatry. 2001 Jul 1;158(7):1001-9.
18. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast
milk, and nursing infants. American Journal of Psychiatry. 2004;161:1066-1078.
19. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR* D) trial: a
review. Canadian Journal of Psychiatry. 2010 Mar;55(3):126-35.
20. Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease—fishing for a natural
treatment. British Medical Journal. 2004 Jan 1;328(7430):30-5.
21. Meyer BJ, Mann NJ, Lewis JL, et al. Dietary intakes and food sources of omega‐6 and omega‐3
polyunsaturated fatty acids. Lipids. 2003 Apr;38(4):391-8.
18 B l e v i n s
22. Hidaka BH, Li S, Harvey KE, et al. Omega-3 and omega-6 Fatty acids in blood and breast tissue of high-risk
women and association with atypical cytomorphology. Cancer Prevention Research. 2015 May 1;8(5):359-
64.
23. Byelashov OA, Sinclair AJ, Kaur G. Dietary sources, current intakes, and nutritional role of omega‐3
docosapentaenoic acid. Lipid Technology. 2015 Apr;27(4):79-82.
24. Gaetan D, Vincent R, Philippe L. The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain
polyunsaturated fatty acid family. Biochimie. 2019 Feb 1.
25. Fish oil concentrate. Lexi-Drugs [Internet]. Lexicomp. Riverwoods, IL: Wolters Kluwer Health, Inc; 2019.
Available from: http://online.lexi.com. Accessed July 9, 2019.
26. Kaur G, Cameron-Smith D, Garg M, et al. Docosapentaenoic acid (22: 5n-3): a review of its biological effects.
Progress in Lipid Research. 2011 Jan 1;50(1):28-34.
27. Omega-3 fatty acids for mood disorders. Harvard Health Blog. Harvard Health Publishing. 2018 Aug 3.
Available from: https://www.health.harvard.edu/blog/omega-3-fatty-acids-for-mood-disorders-
2018080314414. Accessed July 6, 2019.
28. Iso H, Rexrode KM, Stampfer MJ, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women.
Journal of the American Medical Association. 2001 Jan 17;285(3):304-12.
29. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular
disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003 Feb 1;23(2):e20-30.
30. Cunnane S, Drevon CA, Harris B, et al. Recommendations for intake of polyunsaturated fatty acids in healthy
adults. International Society for Study of Fatty Acids and Lipids (ISSFAL) Subcommittee. 2004.
31. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future
research in psychiatry. Journal of Clinical Psychiatry. 2006 Dec 1;67(12):1954-67.
32. Brinson BE, Miller S. Fish oil: what is the role in cardiovascular health? Journal of Pharmacy Practice. 2012
Feb;25(1):69-74.
33. Peanpadungrat P. Efficacy and safety of fish oil in treatment of knee osteoarthritis. Journal of the Medical
Association of Thailand. 2015 Apr 1;98(Suppl 3):S110-4.
34. Glenn JO, Wischmeyer PE. Enteral fish oil in critical illness: perspectives and systematic review. Current
Opinion in Clinical Nutrition & Metabolic Care. 2014 Mar 1;17(2):116-23.
35. Sanchez-Villegas A, Henríquez P, Figueiras A, et al. Long chain omega-3 fatty acids intake, fish consumption
and mental disorders in the SUN cohort study. European Journal of Nutrition. 2007 Sep 1;46(6):337-46.
36. Wani AL, Bhat SA, Ara A. Omega-3 fatty acids and the treatment of depression: a review of scientific
evidence. Integrative Medicine Research. 2015 Sep 1;4(3):132-41.
37. Nutritional psychiatry: your brain on food. Harvard Health Blog. Harvard Health Publishing. 16 Nov 2015.
Available from: https://www.health.harvard.edu/blog/nutritional-psychiatry-your-brain-on-food-
201511168626. Accessed July 3, 2019.
38. Lai JS, Hiles S, Bisquera A, et al. A systematic review and meta-analysis of dietary patterns and depression in
community-dwelling adults. The American Journal of Clinical Nutrition. 2013 Nov 6;99(1):181-97.
39. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, et al. Mediterranean diet, stroke, cognitive impairment,
and depression: a meta‐analysis. Annals of Neurology. 2013 Oct;74(4):580-91.
40. Food and Mood: What Is Nutritional Psychiatry? American Society for Nutrition. 1 Oct 2018. Available from:
https://nutrition.org/food-and-mood-what-is-nutritional-psychiatry/. Accessed July 11, 2019.
41. Hibbeln JR, Nieminen LR, Blasbalg TL, et al. Healthy intakes of n-3 and n-6 fatty acids: estimations
considering worldwide diversity. American Journal of Clinical Nutrition. 2006;83(6 Suppl):1483S-93S.
42. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders.
American Journal of Psychiatry. 2003;160:2222-7.
43. Jacka FN, Cherbuin N, Anstey KJ, et al. Western diet is associated with a smaller hippocampus: a longitudinal
investigation. BMC Medicine. 2015 Dec;13(1):215.
19 B l e v i n s
44. Sarris J, Logan AC, Akbaraly TN, et al. Nutritional medicine as mainstream in psychiatry. The Lancet
Psychiatry. 2015 Mar 1;2(3):271-4.
45. Burhani MD, Rasenick MM. Fish oil and depression: the skinny on fats. Journal of Integrative Neuroscience.
2017 Jan 1;16(s1):S115-24.
46. Stahl LA, Begg DP, Weisinger RS, et al. The role of omega-3 fatty acids in mood disorders. Current Opinion in
Investigational Drugs. 2008 Jan 1;9(1):57-64.
47. Mischoulon D, Freeman MP. Omega-3 fatty acids in psychiatry. Psychiatric Clinics. 2013 Mar 1;36(1):15-23.
48. Lin PY, Mischoulon D, Freeman MP, et al. Are omega-3 fatty acids antidepressants or just mood-improving
agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Molecular
Psychiatry. 2012 Dec;17(12):1161.
49. Natacci L, M Marchioni D, C Goulart A, et al. Omega 3 Consumption and Anxiety Disorders: A Cross-Sectional
Analysis of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Nutrients. 2018 Jun;10(6):663.
50. Kiecolt-Glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation and anxiety
in medical students: a randomized controlled trial. Brain, Behavior, and Immunity. 2011 Nov 1;25(8):1725-
34.
51. Su KP, Tseng PT, Lin PY, et al. Association of use of omega-3 polyunsaturated fatty acids with changes in
severity of anxiety symptoms: A systematic review and meta-analysis. JAMA Network Open. 2018 Sep
7;1(5):e1823-7.
52. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US). 2006.
Available from: https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm. Accessed July 20, 2019.
53. Di Scalea TL, Wisner KL. Antidepressant medication use during breastfeeding. Clinical Obstetrics and
Gynecology. 2009 Sep;52(3):483.
54. Fish Oil, Omega-3 Fatty Acids (Dietary Supplements). Clinical Pharmacology [Internet]. Tampa, FL: Elsevier;
2018. Available from: http://www.clinicalpharmacology.com. Accessed July 5, 2019.
55. Blanchard LB, McCarter GC. Insomnia and exacerbation of anxiety associated with high-EPA fish oil
supplements after successful treatment of depression. Oxford Medical Case Reports. 2015 Mar
1;2015(3):244-5.
56. Lesperance F, Frasure-Smith N, St-Andre E, et al. The efficacy of omega-3 supplementation for major
depression: a randomized controlled trial. Journal of Clinical Psychiatry. 2011;72:1054–62.
57. Jacka FN, Pasco JA, Williams LJ, et al. Dietary intake of fish and PUFA, and clinical depressive and anxiety
disorders in women. British Journal of Nutrition. 2013 Jun;109(11):2059-66.
58. Fux M, Benjamin J, Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. Journal of
Psychiatric Research. 2004 May 1;38(3):323-5.
59. Zeev K, Michael M, Ram K, et al. Possible deleterious effects of adjunctive omega-3 fatty acids in post-
traumatic stress disorder patients. Neuropsychiatric Disease and Treatment. 2005 Jun;1(2):187.
60. Buydens-Branchey L, Branchey M, Hibbeln JR. Associations between increases in plasma n-3
polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance
abusers. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008 32(2), pp.568-75.
61. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. Arlington, VA:
American Psychiatric Association, 2010. Available from:
https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/mdd.pdf. Accessed July 5, 2019.
62. Bozzatello P, Brignolo E, De Grandi E, et al. Supplementation with omega-3 fatty acids in psychiatric
disorders: a review of literature data. Journal of Clinical Medicine. 2010 Oct;5(8):67.
20 B l e v i n s
Appendices
Appendix A. Antidepressant classes and agents
Selective Serotonin Reuptake Inhibitors (SSRIs)
Citalopram, escitalopram, fluoxetine, paroxetine, sertraline
Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)
Duloxetine, venlafaxine, levomilnacipran, desvenlafaxine, milnacipran
Norepinephrine/Dopamine Reuptake Inhibitor (NDRI)
Bupropion
Tricyclic Antidepressants (TCAs) Amitriptyline, imipramine, nortriptyline, desipramine, doxepin, amoxapine, clomipramine, maprotiline, protriptyline, trimipramine
Monoamine Oxidase Inhibitors (MAOIs) Isocarboxazid, phenelzine, selegiline, tranylcypromine
Other/Atypical Antidepressants Vortioxetine, trazodone, nefazodone, mirtazapine, vilazodone
Appendix B. Additional pharmacological agents for treatment of anxiety disorders
Appendix C. Symptom rating scales for GAD
Scale Description Scoring
Hamilton Anxiety Scale (HAM-A)
Gold standard for GAD symptoms; 14-item scale Clinician-rated
Mild: 0-17 Mild-moderate: 18-24 Moderate-severe: 25-30
Generalized Anxiety Disorder 7-item Scale (GAD-7)
Commonly used in practice for GAD; 7-item scale Patient self-report (assess symptoms over last 2 weeks)
None: 0-5 Mild: 6-10 Moderate: 11-15 Severe: 16-21
Beck Anxiety Inventory (BAI)
Distinguishes anxiety (GAD) from depression; 21-item scale Patient self-report
Minimal: 0-7 Mild: 8-15 Moderate: 16-25 Severe: 26-63
Hydroxyzine
Sedating, first-generation antihistamine
Usually short-term acute treatment of GAD, up to 4 weeks
Beta-blockers
Atenolol or propranolol or pindolol
May provide relief for physical symptoms of anxiety, such as tremor, palpitations, and shortness of breath
Buspirone
Anxiolytic
Usually short-term acute treatment of GAD
Anticonvulsants
Gabapentin
Valproic acid
Pregabalin
Structural analog of gamma-aminobutyric acid (GABA)
Monotherapy or augmentation of antidepressants in GAD
Quetiapine
Second-generation/atypical antipsychotic
Monotherapy in GAD or augmentation of antidepressants in OCD or PTSD
Typically reserved for treatment-resistance
Benzodiazepines
Clonazepam, lorazepam, alprazolam, diazepam, chlordiazepoxide, temazepam
Rapid symptomatic relief for acute distress
LIMIT USE